Skip to main content

Penmenvy Dosage

Generic name: NEISSERIA MENINGITIDIS GROUP A CAPSULAR OLIGOSACCHARIDE DIPHTHERIA CRM197 PROTEIN CONJUGATE ANTIGEN 10ug in 0.5mL, NEISSERIA MENINGITIDIS GROUP C CAPSULAR OLIGOSACCHARIDE DIPHTHERIA CRM197 PROTEIN CONJUGATE ANTIGEN 5ug in 0.5mL, NEISSERIA MENINGITIDIS GROUP W-135 CAPSULAR OLIGOSACCHARIDE DIPHTHERIA CRM197 PROTEIN CONJUGATE ANTIGEN 5ug in 0.5mL, NEISSERIA MENINGITIDIS GROUP Y CAPSULAR OLIGOSACCHARIDE DIPHTHERIA CRM197 PROTEIN CONJUGATE ANTIGEN 5ug in 0.5mL; NEISSERIA MENINGITIDIS GROUP B NHBA FUSION PROTEIN ANTIGEN 50ug in 0.5mL, NEISSERIA MENINGITIDIS GROUP B FHBP FUSION PROTEIN ANTIGEN 50ug in 0.5mL, NEISSERIA MENINGITIDIS GROUP B NADA PROTEIN ANTIGEN 50ug in 0.5mL, NEISSERIA MENINGITIDIS GROUP B STRAIN NZ98/254 OUTER MEMBRANE VESICLE 25ug in 0.5mL
Dosage form: injectable suspension, intramuscular

Medically reviewed by Drugs.com. Last updated on Feb 14, 2025.

For intramuscular use.

Dose and Schedule

Administer 2 doses (approximately 0.5 mL each) of PENMENVY 6 months apart.

Preparation

PENMENVY is supplied as one vial of Lyophilized MenACWY Component (powder) and one prefilled syringe of MenB Component (liquid) which must be combined before administration.

Use only the supplied MenB Component to reconstitute the Lyophilized MenACWY Component.

Figure 1

Figure 1. Invert the prefilled syringe of the MenB Component multiple times to form a homogeneous suspension. Do not use the prefilled syringe of the MenB Component if it cannot be resuspended.

Figure 2

Figure 2. Hold the syringe by the barrel. Unscrew the syringe cap by twisting it counterclockwise.

Figure 3

Figure 3. Connect the hub of a sterile needle to the Luer Lock Adaptor of the prefilled syringe of the MenB Component and rotate a quarter turn clockwise until it locks.

Figure 4

Figure 4. Cleanse the stopper of the vial containing the Lyophilized MenACWY Component. Slowly transfer the entire contents of the syringe into the vial containing the Lyophilized MenACWY Component.

Figure 5

Figure 5. Without removing the needle from the vial, swirl the vial gently until powder is completely dissolved. Do not invert the vial or shake vigorously.

Figure 6

Figure 6. After reconstitution, invert the vial and withdraw the entire contents.

PENMENVY is a white opalescent suspension. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. If either of these conditions exist, PENMENVY should not be administered.

Administration

Administer intramuscularly.

Administer PENMENVY immediately after reconstitution.

More about Penmenvy (meningococcal group acwy conjugate-group b vaccine (cvx 328))

Patient resources

Professional resources

Related treatment guides

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.